Drug prescribing in renal failure: dosing guidelines for adults.

The data base for rational guidelines to safe, efficacious drug prescribing in adults with renal insufficiency are presented in tabular form. Current medical literature was extensively surveyed to provide as much specific information as possible. When information is lacking, however, recommendations are based on pharmacokinetic variables in normal subjects. Nephrotoxicity, important adverse effects, and special considerations in renal patients are noted. Adjustments are suggested for hemodialysis and peritoneal dialysis when appropriate.

[1]  L. Nelson,et al.  Kinetics of procainamide and N-acetylprocainamide in renal failure. , 1977, Kidney international.

[2]  F. Port,et al.  Lithium therapy during maintenance hemodialysis. , 1979, Psychosomatics.

[3]  P. Galletti,et al.  Hemodialysis in cancer chemotherapy. , 1966, Transactions - American Society for Artificial Internal Organs.

[4]  R. L. Felsted,et al.  Comparative mammalian metabolism of adriamycin and daunorubicin. , 1978, Cancer research.

[5]  F. Luft,et al.  Pharmacokinetics of Netilmicin in Patients with Renal Impairment and in Patients on Dialysis , 1978, Antimicrobial Agents and Chemotherapy.

[6]  O. Schück,et al.  The binding of chloramphenicol to serum proteins in patients with chronic renal insufficiency. , 1976, Clinical Nephrology.

[7]  R. Ohman,et al.  Pharmacokinetic studies on haloperidol in man. , 1976, Current therapeutic research, clinical and experimental.

[8]  B. Berkowitz.  The Relationship of Pharmacokinetics to Pharmacological Activity: Morphine, Methadone and Naloxone , 1976, Clinical pharmacokinetics.

[9]  L. F. Fajardo,et al.  Allopurinol-induced interstitial nephritis. , 1977, Annals of internal medicine.

[10]  W. Pettinger.  Pharmacology of Clonidine , 1980, Journal of cardiovascular pharmacology.

[11]  D. Ho,et al.  Clinical pharmacology of l‐β‐D‐arabinofuranosyl cytosine , 1971 .

[12]  G. Siber,et al.  Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. , 1982, Reviews of infectious diseases.

[13]  N. Benowitz,et al.  Peritoneal clearance and total body elimination of vancomycin during chronic intermittent peritoneal dialysis. , 1979, Clinical nephrology.

[14]  R. Vigorito,et al.  Acute renal failure and renal tubular squamous metaplasia following treatment with streptozotocin. , 1982, Human pathology.

[15]  A. Karim,et al.  Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. , 1978, Drug metabolism reviews.

[16]  J. Doluisio.  Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function. , 1982, Reviews of infectious diseases.

[17]  D. Perrier,et al.  Digoxin‐Quinidine Interaction in Patients with Chronic Renal Failure , 1982, Circulation.

[18]  T. L. Evans,et al.  Kinetics of intravenous melphalan , 1979, Clinical pharmacology and therapeutics.

[19]  R. Venuto,et al.  Cephalothin handling in patients undergoing hemodialysis. , 1970, Antimicrobial agents and chemotherapy.

[20]  J. Rotschafer,et al.  Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations , 1982, Antimicrobial Agents and Chemotherapy.

[21]  W. Colucci,et al.  Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications. , 1982, Annals of internal medicine.

[22]  C. George.  Amiloride handling in renal failure. , 1980, British journal of clinical pharmacology.

[23]  P. Vereerstraeten,et al.  125I-insulin metabolism in chronic renal failure treated by renal transplantation. , 1974, Kidney international.

[24]  W. Steinbrunn,et al.  Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. , 1973, Annals of internal medicine.

[25]  J. Clements,et al.  Clinical Pharmacokinetics of Paracetamol , 1982, Clinical pharmacokinetics.

[26]  T. Ing,et al.  Amantadine toxicity in a patient with renal insufficiency. , 1974, Nephron.

[27]  J. Mendels,et al.  The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. , 1980, The American journal of psychiatry.

[28]  S. Warrington,et al.  Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment. , 1980, British journal of clinical pharmacology.

[29]  M. Ohkawa,et al.  Elimination kinetics of ceftizoxime in humans with and without renal insufficiency , 1982, Antimicrobial Agents and Chemotherapy.

[30]  T. Blaschke,et al.  Disposition of ketoconazole, an oral antifungal, in humans , 1982, Antimicrobial Agents and Chemotherapy.

[31]  R. Millard.  Busulphan haemorrhagic cystitis. , 1978, British journal of urology.

[32]  P. Weidmann,et al.  beta blockade with pindolol: differential cardiac and renal effects despite similar plasma kinetics in normal and uremic man. , 1979, Kidney international.

[33]  A. Goldberg,et al.  Control of clofibrate toxicity in uremic hypertriglyceridemia , 1977, Clinical pharmacology and therapeutics.

[34]  F. Luft,et al.  Moxalactam pharmacokinetics during hemodialysis , 1981, Antimicrobial Agents and Chemotherapy.

[35]  E. Triggs,et al.  Pharmacokinetic studies of tolmetin in man , 1975, Clinical pharmacology and therapy.

[36]  S. J. Matthews,et al.  Disopyramide hemodialysis and kinetics in patients requiring long‐term hemodialysis , 1981, Clinical pharmacology and therapeutics.

[37]  J. Koch-weser,et al.  Drug therapy: metronidazole. , 1980, The New England journal of medicine.

[38]  L. Hendeles,et al.  Monitoring Serum Theophylline Levels , 1978, Clinical pharmacokinetics.

[39]  R. E. Peterson.  METABOLISM OF ADRENOCORTICOSTEROIDS IN MAN , 1959, Annals of the New York Academy of Sciences.

[40]  W. Bennett.  Drugs and the Kidney , 1981 .

[41]  P. D. Henry.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. , 1980, The American journal of cardiology.

[42]  Swartz Mn,et al.  Drug therapy: antiviral agents (first of two parts). , 1980 .

[43]  H. G. Morgan,et al.  Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure , 1974, Clinical pharmacology and therapeutics.

[44]  Rahn Kh.  The influence of renal function on plasma levels, urinary excretion, metabolism, and antihypertensive effect of guanethidine (ismelin) in man. , 1973 .

[45]  C. Comty,et al.  Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis , 1981, Antimicrobial Agents and Chemotherapy.

[46]  S. Liao,et al.  Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. , 1982, The American journal of medicine.

[47]  E. Hvidberg,et al.  Elimination of oral cimetidine in chronic renal failure and during haemodialysis. , 1980, British journal of clinical pharmacology.

[48]  A. Sebastian,et al.  Renal and systemic acid-base effects of chronic spironolactone administration. , 1981, The American journal of physiology.

[49]  R. Schilsky,et al.  Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. , 1979, Annals of internal medicine.

[50]  R. Zelis,et al.  Calcium blocking drugs for angina pectoris. , 1982, Annual review of medicine.

[51]  M. Dunnill,et al.  Acute renal failure associated with diflunisal , 1982, Postgraduate medical journal.

[52]  H. Don,et al.  Narcotic analgesics in anuric patients. , 1975, Anesthesiology.

[53]  D. Stanski,et al.  Pharmacokinetics of edrophonium in anephric and renal transplant patients. , 1981, British journal of anaesthesia.

[54]  J. Mann,et al.  Treatment of hyperlipidaemia in patients on chronic haemodialysis. , 1978, British medical journal.

[55]  J. Abrams.  Nitroglycerin and long-acting nitrates. , 1980, The New England journal of medicine.

[56]  S. Sternberg,et al.  The renal pathology in clinical trials of Cis‐platinum (II) diamminedichloride , 1977, Cancer.

[57]  M G Myers,et al.  Metoprolol kinetics and dose response in hypertensive patients , 1980, Clinical pharmacology and therapeutics.

[58]  O. Laskin.  Clinical Pharmacokinetics of Acyclovir , 1983, Clinical pharmacokinetics.

[59]  D. Shand,et al.  Antenolol: A Long-Acting Beta1-Adrenoceptor Antagonist , 1982 .

[60]  H. Neu.  The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics. , 1982, Annual review of pharmacology and toxicology.

[61]  H. Mattie,et al.  Dicloxacillin and cloxacillin: Pharmacokinetics in healthy and hemodialysis subjects , 1976, Clinical pharmacology and therapeutics.

[62]  M. Reichgott.  Minoxidil and pericardial effusion: An idiosyncratic reaction , 1981, Clinical pharmacology and therapeutics.

[63]  J. Bach,et al.  THE METABOLISM OF AZATHIOPRINE IN RENAL FAILURE , 1971, Transplantation.

[64]  B. Kennedy.  Metabolic and toxic effects of mithramycin during tumor therapy. , 1970, The American journal of medicine.

[65]  D. Lowenthal,et al.  Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients , 1975, Clinical pharmacology and therapeutics.

[66]  J. Rapoport,et al.  Active metabolites of imipramine and desipramine in man , 1982, Clinical pharmacology and therapeutics.

[67]  D. Bourne,et al.  The Pharmacology of Verapamil. III. Pharmacokinetics in Normal Subjects After Intravenous Drug Administration , 1981, Journal of cardiovascular pharmacology.

[68]  M. Molzahn,et al.  Effect of plasma protein binding, volume of distribution and molecular weight on the fraction of drugs eliminated by hemodialysis. , 1983, Clinical nephrology.

[69]  S. Katz,et al.  Tolmetin. Association with reversible renal failure and acute interstitial nephritis. , 1981, JAMA.

[70]  C. Anastassiades.  Nifedipine and beta-blocker drugs. , 1980, British medical journal.

[71]  L. Einhorn,et al.  Long term effect of Cis‐Diamminedichloride platinum (CDDP) on renal function and structure in man , 1978, Cancer.

[72]  M. Aitio.  Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy. , 1981, British journal of clinical pharmacology.

[73]  G. R. Nakamura,et al.  Persistence of morphine in blood in association with hepatic necrosis and renal tubular necrosis. , 1980, Journal of forensic sciences.

[74]  M. H. Gault,et al.  Loading dose of digoxin in renal failure. , 1980, British journal of clinical pharmacology.

[75]  J. Hamilton-miller,et al.  Methenamine and its salts as urinary tract antiseptics: variables affecting the antibacterial activity of formaldehyde, mandelic acid, and hippuric acid in vitro. , 1977, Investigative urology.

[76]  E. Holten,et al.  Concentration of metronidazole in serum during peritoneal dialysis. , 1981, Chemotherapy.

[77]  M. Root,et al.  Pharmacokinetics of vindesine and vincristine in humans. , 1977, Cancer research.

[78]  James A. Taylor.  Pharmacokinetics and biotransformation of chlorpropamide in man , 1972, Clinical pharmacology and therapeutics.

[79]  D. Greenblatt,et al.  Clinical use of the benzodiazepines. , 1981, Rational drug therapy.

[80]  R. Ogilvie.  Clinical Pharmacokinetics of Theophylline , 1978, Clinical pharmacokinetics.

[81]  M. Rudnick,et al.  Renal failure, hemodialysis, and nafcillin kinetics , 1976, Clinical pharmacology and therapeutics.

[82]  F. Balis,et al.  Clinical Pharmacokinetics of Commonly Used Anticancer Drugs , 1983, Clinical pharmacokinetics.

[83]  P. Vlasses,et al.  Clinical pharmacology and therapeutic applications of the new oral angiotensin converting enzyme inhibitor, captopril. , 1981, American heart journal.

[84]  D. Shen,et al.  Clinical Pharmacokinetics of Methotrexate , 1978, Clinical pharmacokinetics.

[85]  N. Holford,et al.  Prednisone and prednisolone bioavailability in renal transplant patients. , 1982, Kidney international.

[86]  F. Donati,et al.  Antagonism of pancuronium in renal failure: no recurarization. , 1982, British journal of anaesthesia.

[87]  H. Dargie,et al.  Nifedipine and propranolol: a beneficial drug interaction. , 1981, The American journal of medicine.

[88]  H. Neu,et al.  Intravenous azlocillin kinetics in patients on long‐term hemodialysis , 1980, Clinical pharmacology and therapeutics.

[89]  C. Regårdh,et al.  Clinical Pharmacokinetics of Metoprolol , 1980, Clinical pharmacokinetics.

[90]  M. E. Jaffe,et al.  METABOLISM OF CARBIDOPA [L-(-)-α-HYDRAZINO-3,4-DIHYDROXY-α-METHYLHYDROCINNAMIC ACID MONOHYDRATE], AN AROMATIC AMINO ACID DECARBOXYLASE INHIBITOR, IN THE RAT, DOG, RHESUS MONKEY, AND MAN , 1974 .

[91]  B. Kågedal,et al.  The effect of cimetidine, a new histamine H2-receptor antagonist, on renal function. , 2009, Acta medica Scandinavica.

[92]  D. Spyker,et al.  Pharmacokinetics of Amoxicillin: Dosage Nomogram for Patients with Impaired Renal Function , 1979, Antimicrobial Agents and Chemotherapy.

[93]  P. Somani,et al.  Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis , 1982, Clinical pharmacology and therapeutics.

[94]  A. Nicolai,et al.  Clofibrate treatment of hyperlipidemia in chronic renal failure. , 1977, Clinical nephrology.

[95]  D. Shen,et al.  Disposition kinetics of disopyramide in patients with renal insufficiency , 1980, Biopharmaceutics & drug disposition.

[96]  R. N. Brogden,et al.  Metoclopramide. An updated review of its pharmacological properties and clinical use. , 1983, Drugs.

[97]  G. Bacon,et al.  Prolonged serum half-life of cortisol in renal failure. , 1973, The Johns Hopkins medical journal.

[98]  W. Bennett,et al.  Efficacy and safety of metolazone in renal failure and the nephrotic syndrome. , 1973, Journal of clinical pharmacology.

[99]  J. Perel,et al.  THE METABOLISM OF PROBENECID IN MAN * , 1971, Annals of the New York Academy of Sciences.

[100]  Nonsteroidal Antiinflammatory Drugs , 1980 .

[101]  W. Bennett,et al.  Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics. , 1980, Annals of internal medicine.

[102]  L. Benet,et al.  Disposition of Zomepirac Sodium in Man , 1982, Journal of clinical pharmacology.

[103]  G. H. Nancollas,et al.  Triamterene and renal stone formation. , 1982, The Journal of urology.

[104]  R. Glassock,et al.  Pindolol: effects on blood pressure and plasma renin activity. , 1982, American heart journal.

[105]  M. Jarman,et al.  Haemodialysis during cyclophosphamide treatment. , 1978, British medical journal.

[106]  W. Bennett,et al.  Structural and functional effects of long-term lithium therapy. , 1982, Kidney international. Supplement.

[107]  T. Ludden,et al.  Plasma Concentration and Acetylator Phenotype Determine Response to Oral Hydralazine , 1981, Hypertension.

[108]  B. Wilder,et al.  Protein binding Of valproic acid in uremic patients , 1980, Neurology.

[109]  P. Hopewell,et al.  Tuberculosis in patients with end-stage renal disease. , 1980, The American journal of medicine.

[110]  T. Chin,et al.  Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis. , 1981, Clinical and experimental dialysis and apheresis.

[111]  L. Sennello,et al.  Cefsulodin kinetics in renal impairment , 1982, Clinical pharmacology and therapeutics.

[112]  N. Ertel,et al.  Colchicine plasma levels. Implications as to pharmacology and mechanism of action. , 1970, The American journal of medicine.

[113]  E. Kinney,et al.  The pharmacokinetics of diltiazem in healthy American men. , 1982, The American journal of cardiology.

[114]  P. Verroust,et al.  Drug Intoxication and Neurological Episodes in Chronic Renal Failure , 1970, British medical journal.

[115]  W. Frishman.  Atenolol and Timolol, Two New Systemic β-Adrenoceptor Antagonists , 1982 .

[116]  L. Pickering,et al.  Effect of concentration and time upon inactivation of tobramycin, gentamicin, netilmicin and amikacin by azlocillin, carbenicillin, mecillinam, mezlocillin and piperacillin. , 1981, The Journal of pharmacology and experimental therapeutics.

[117]  A. Pierides,et al.  CLOFIBRATE-INDUCED MUSCLE DAMAGE IN PATIENTS WITH CHRONIC RENAL FAILURE , 1975, The Lancet.

[118]  C. Hertz.  Serum and Urinary Concentrations of Cyclacillin in Humans , 1973, Antimicrobial Agents and Chemotherapy.

[119]  H. E. Hansen,et al.  Peritoneal transport of vancomycin during peritoneal dialysis. , 1979, Nephron.

[120]  L. Sheiner,et al.  Pyridostigmine kinetics with and without renal function , 1980, Clinical pharmacology and therapeutics.

[121]  S. Chiang,et al.  Renal disease, age, and oxazepam kinetics , 1981, Clinical pharmacology and therapeutics.

[122]  G. Eknoyan,et al.  Minocycline and doxycycline kinetics in chronic renal failure , 1978, Clinical pharmacology and therapeutics.

[123]  Bailey Rr,et al.  The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin. , 1970 .

[124]  L. Benet,et al.  The pharmacokinetics of d-tubocurarine in man with and without renal failure. , 1977, The Journal of pharmacology and experimental therapeutics.

[125]  B. Kaufmann,et al.  Pharmacokinetics of Metildigoxin and Digoxin in Geriatric Patients with Normal and Elevated Serum Creatinine Levels , 1981, Clinical pharmacokinetics.

[126]  Sarubbi Fa,et al.  Amikacin Serum Concentrations: Prediction of Levels and Dosage Guidelines , 1978 .

[127]  C. Shanks,et al.  Gallamine disposition in surgical patients with chronic renal failure. , 1981, British journal of clinical pharmacology.

[128]  A. Atkinson,et al.  N‐Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis , 1979, Clinical pharmacology and therapeutics.

[129]  E. Schneeberger,et al.  Chronic renal failure in children treated with methyl CCNU. , 1979, The New England journal of medicine.

[130]  P. Larsen,et al.  Prevalence of abnormal thyroid function test results in patients with acute medical illnesses. , 1982, The American journal of medicine.

[131]  N. Bachur,et al.  High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. , 1981, Cancer treatment reports.

[132]  A. Ridolfo,et al.  Nonsteroidal anti-inflammatory agents. , 1979, Annual review of pharmacology and toxicology.

[133]  T. L. Evans,et al.  Oral melphalan kinetics , 1979, Clinical pharmacology and therapeutics.

[134]  Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis , 1982, Antimicrobial Agents and Chemotherapy.

[135]  T. Zsotér,et al.  Excretion and metabolism of reserpine In renal failure , 1973, Clinical pharmacology and therapeutics.

[136]  Robert J. Anderson,et al.  Clinical use of drugs in patients with kidney and liver disease , 1981 .

[137]  B. Hoogstraten,et al.  Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. , 1974, Cancer research.

[138]  P. Perry,et al.  Heparin half‐life in normal and impaired renal function , 1974, Clinical pharmacology and therapy.

[139]  J. Wagner,et al.  Clinical Pharmacokinetics of Intravenous and Oral Bretylium Tosylate in Survivors of Ventricular Tachycardia or Fibrillation: Clinical Application of a New Assay for Bretylium , 1981, Journal of cardiovascular pharmacology.

[140]  S. Crooke,et al.  Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function , 1977, Cancer.

[141]  C. Alling,et al.  Renal function and biopsy findings in patients on long-term lithium treatment. , 1981, Kidney international.

[142]  M. Rawlins,et al.  Pharmacokinetics of pancuronium in patients with normal and impaired renal function. , 1976, British journal of anaesthesia.

[143]  H. Meyer‐Rienecker,et al.  [On nitrofurantoin-polyneuropathy]. , 1966, Der Nervenarzt.

[144]  H. Dash,et al.  Letter: Severe metabolic acidosis associated with nalidixic acid overdose. , 1976, Annals of internal medicine.

[145]  M. Velasco,et al.  Decreased plasma protein binding of diazoxide in uremia , 1975, Clinical pharmacology and therapeutics.

[146]  D. Greenblatt,et al.  Clinical Pharmacokinetics of Chlordiazepoxide , 1975, Psychopharmacology bulletin.

[147]  R. Ogilvie,et al.  Cefoxitin disposition during peritoneal dialysis , 1981, Antimicrobial Agents and Chemotherapy.

[148]  D. Greenblatt,et al.  Prazepam and lorazepam, two new benzodiazepines. , 1978, The New England journal of medicine.

[149]  J. A. Mills.  Nonsteroidal Anti-Inflammatory Drugs , 1974 .

[150]  M. Sweeney,et al.  Effect of Hemodialysis and Renal Failure on Serum and Urine Concentrations of Cephapirin Sodium , 1972, Antimicrobial Agents and Chemotherapy.

[151]  T. N. Calvey,et al.  Renal clearance of pyridostigmine in patients with myasthenia gravis. , 1977, European neurology.

[152]  R. Ings,et al.  The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. , 1982, Reviews of infectious diseases.

[153]  J. Judis.  Binding of sulfonylureas to serum proteins. , 1972, Journal of pharmaceutical sciences.

[154]  D. Lowenthal.  Pharmacokinetics of Clonidine , 1980, Journal of cardiovascular pharmacology.

[155]  M. Viederman,et al.  Psychotherapeutic agents in renal failure. , 1977, The American journal of medicine.

[156]  A. Schecter,et al.  Methadone use in patients with chronic renal disease. , 1980, Drug and alcohol dependence.

[157]  R. D. Meyer,et al.  Drugs Five Years Later: Amikacin , 1981 .

[158]  G. Bodemar,et al.  Steady-state Kinetics and Dosage Requirements of Cimetidine in Renal Failure , 1981, Clinical pharmacokinetics.

[159]  D. Lowenthal,et al.  Kinetics of salicylate elimination by anephric patients. , 1974, The Journal of clinical investigation.

[160]  G. Eliopoulos,et al.  Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. , 1982, Annals of internal medicine.

[161]  D. Breimer,et al.  Clinical Pharmacokinetics of Hypnotics , 1977, Clinical pharmacokinetics.

[162]  S. Crooke,et al.  Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. , 1977, Cancer treatment reports.

[163]  R. Cutler,et al.  Flucytosine kinetics in subjects with normal and impaired renal function , 1978, Clinical pharmacology and therapeutics.

[164]  S. Symchowicz,et al.  Metabolism of chlorpheniramine maleate in man. , 1972, The Journal of pharmacology and experimental therapeutics.

[165]  R. Cutler,et al.  Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure. , 1982, Nephron.

[166]  M. van Gemert,et al.  Clofibrate-induced antidiuresis. , 1973, The Journal of clinical investigation.

[167]  M. Houston.  Clonidine hydrochloride: review of pharmacologic and clinical aspects. , 1981, Progress in cardiovascular diseases.

[168]  G. Dette,et al.  Pharmakokinetics of Erythromycin , 1977, Scottish medical journal.

[169]  L. Benet,et al.  Cefamandole kinetics in uremic patients undergoing hemodialysis , 1979, Clinical pharmacology and therapeutics.

[170]  D. Greenblatt,et al.  Clinical Pharmacokinetics of Quinidine , 1980, Clinical pharmacokinetics.

[171]  D. Lowenthal,et al.  Prazosin kinetics and effectiveness in renal failure , 1980, Clinical pharmacology and therapeutics.

[172]  J. Feldman,et al.  The pharmacology of sulfonylureas. , 1981, The American journal of medicine.

[173]  K. Lynn,et al.  Nortriptyline metabolism in chronic renal failure: Metabolite elimination , 1982, Clinical pharmacology and therapeutics.

[174]  M. Hyneck,et al.  Cimetidine clearance during intermittent and chronic peritoneal dialysis. , 1981, American journal of hospital pharmacy.

[175]  B. Scribner,et al.  Acetate and bicarbonate fluctuations and acetate intolerance during dialysis. , 1982, Kidney international.

[176]  J. Bull,et al.  Kinetics of cis‐dichlorodiammineplatinum , 1979, Clinical pharmacology and therapeutics.

[177]  R. Branch,et al.  Drug Metabolites in Renal Failure , 1981 .

[178]  P. Reece,et al.  Kinetics of hydralazine and its main metabolites in slow and fast acetylators , 1980, Clinical pharmacology and therapeutics.

[179]  W. Murphy,et al.  Renal disease after mitomycin c therapy , 1981, Cancer.

[180]  P. Fenster,et al.  Digitoxin-quinidine interaction: pharmacokinetic evaluation. , 1980, Annals of internal medicine.

[181]  C. Inturrisi.  Disposition of narcotics in patients with renal disease. , 1977, The American journal of medicine.

[182]  D. Drayer,et al.  Cumulation of N‐acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function , 1977, Clinical pharmacology and therapeutics.

[183]  A. Iaina,et al.  Cholestyramine in uraemic pruritus. , 1977, British medical journal.

[184]  D. Cullen,et al.  Renal failure and postoperative respiratory failure: recurarization? , 1976, British journal of anaesthesia.

[185]  R. Kates,et al.  Verapamil protein binding in patients and in normal subjects , 1981, Clinical pharmacology and therapeutics.

[186]  J. Thorp,et al.  Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia. , 1972, Lancet.

[187]  P. Jatlow,et al.  Resin hemoperfusion for treatment of ethchlorvynol overdose. , 1979, Annals of internal medicine.

[188]  B. Strates,et al.  Metabolism and pharmacokinetics of the antibiotic rifampin. , 1981, Drug metabolism reviews.

[189]  J. Lowenstein.  Drugs five years later: clonidine. , 1980, Annals of internal medicine.

[190]  Effect of hemodialysis on total body clearance of chloramphenicol. , 1980, American journal of hospital pharmacy.

[191]  D. O'Connor,et al.  Hyperkalemia resulting from captopril administration. , 1980, JAMA.

[192]  D. Lowenthal,et al.  Pharmacology and Pharmacokinetics of Minoxidil , 1980, Journal of cardiovascular pharmacology.

[193]  J. Killander,et al.  Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. , 1975, The Journal of urology.

[194]  E. Mroszczak,et al.  Naproxen‐probenecid interaction , 1978, Clinical pharmacology and therapeutics.

[195]  U Boerner,et al.  The metabolism of morphine and heroin in man. , 1975, Drug metabolism reviews.

[196]  S. Rosenberg,et al.  Methotrexate and hemodialysis. , 1977, Annals of internal medicine.

[197]  J. Bruni,et al.  Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. , 1980, Clinical toxicology.

[198]  R. Eisinger,et al.  Indomethacin-associated acute renal failure. , 1980, The American journal of medicine.

[199]  C. Ditzler,et al.  The disposition of sulindac , 1977, Clinical pharmacology and therapeutics.

[200]  K. Schenck-Gustafsson,et al.  Effect of quinidine on plasma concentration and renal clearance of digoxin. A clinically important drug interaction. , 1980, British journal of clinical pharmacology.

[201]  R. H. Meade.  Drug therapy reviews: clinical pharmacology and therapeutic use of antimycotic drugs. , 1979, American journal of hospital pharmacy.

[202]  Trefor Owen Morgan,et al.  Effects of lithium on the kidney. , 1980, Kidney international.

[203]  M. Tattersall,et al.  Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease. , 1978, European journal of cancer.

[204]  W. Jusko,et al.  Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment , 1982, Antimicrobial Agents and Chemotherapy.

[205]  R. Ogilvie,et al.  Diazoxide concentration-response relation in hypertension. , 1982, Hypertension.

[206]  N. Buchanan,et al.  Isoniazid pharmacokinetics in patients in chronic renal failure. , 1976, Clinical nephrology.

[207]  Borison Rl.  Amantadine-induced psychosis in a geriatric patient with renal disease. , 1979 .

[208]  C. Hoppel,et al.  Plasma levels and renal excretion of phenytoin and its metabolites in patients with renal failure , 1979, Clinical pharmacology and therapy.

[209]  P. Edlund,et al.  Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy. , 1981, British journal of clinical pharmacology.

[210]  D. Fung,et al.  Fentanyl Pharmacokinetics in Awake Volunteers , 1980, Journal of clinical pharmacology.

[211]  V. Oliverio,et al.  The pharmacokinetics of [3H]‐vincristine in man , 1977, Clinical pharmacology and therapeutics.

[212]  C. Regårdh,et al.  The Effect of Impaired Renal Function on the Plasma Concentration and Urinary Excretion of Metoprolol Metabolites , 1980, Clinical pharmacokinetics.

[213]  L. J. Fischer,et al.  Glutethimide poisoning. A metabolite contributes to morbidity and mortality. , 1975, The New England journal of medicine.

[214]  B. Beermann,et al.  Clinical Pharmacokinetics of Diuretics , 1980, Clinical pharmacokinetics.

[215]  E. Block,et al.  Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. , 1974, Annals of internal medicine.

[216]  D. Kaye,et al.  Pharmacology of Intraperitoneal Cefazolin in Patients Undergoing Peritoneal Dialysis , 1978, Antimicrobial Agents and Chemotherapy.

[217]  R. Stote,et al.  Effect of cimetidine on renal function in normal man , 1978, Clinical pharmacology and therapeutics.

[218]  B. Bean,et al.  Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects , 1981, Antimicrobial Agents and Chemotherapy.

[219]  M. Neff,et al.  Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndrome. , 1982, Archives of internal medicine.

[220]  P. Welling,et al.  Pharmacokinetics of intravenous erythromycin. , 1978, Journal of pharmaceutical sciences.

[221]  M E Pickup,et al.  Clinical Pharmacokinetics of Prednisone and Prednisolone , 1979, Clinical pharmacokinetics.

[222]  F. Belpaire,et al.  WARFARIN ELIMINATION AND RESPONSIVENESS IN PATIENTS WITH RENAL DYSFUNCTION , 1978, Journal of clinical pharmacology.

[223]  F. Luft,et al.  Cisplatin pharmacokinetics in a patient with renal dysfunction. , 1978, Medical and pediatric oncology.

[224]  W. Frishman.  Nadolol: A New β-Adrenoceptor Antagonist , 1981 .

[225]  P. Zafiracopoulos,et al.  Letter: Breast cancer at site of implantation of pacemaker generator. , 1974, Lancet.

[226]  R. Verbeeck,et al.  Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding , 1980, Clinical pharmacology and therapeutics.

[227]  T. Marbury,et al.  Pharmacokinetics of Primidone Elimination by Uremic Patients , 1982, Journal of clinical pharmacology.

[228]  C. Mogensen,et al.  The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects , 1982, European journal of clinical investigation.

[229]  P. Ivanovich,et al.  Hemoperfusion for methotrexate removal , 1978, Clinical pharmacology and therapeutics.

[230]  F. Nielsen‐Kudsk,et al.  Digoxin‐verapamil interaction , 1981, Clinical pharmacology and therapeutics.

[231]  S. Rosansky,et al.  Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis , 1983, Antimicrobial Agents and Chemotherapy.

[232]  S. Goldfarb,et al.  Effects of methyldopa on renal hemodynamics and tubular function , 1980, Clinical pharmacology and therapeutics.

[233]  R. Ogilvie,et al.  Metabolic disposition of diphenhydramine , 1974, Clinical pharmacology and therapeutics.

[234]  C. Brown,et al.  High dose frusemide in acute renal failure: a controlled trial. , 1981, Clinical nephrology.

[235]  C. Southam.  Co-existence of allogeneic tumour growth and homograft immunity in man. , 1968, European journal of cancer.

[236]  P. Zech,et al.  Nalidixic acid kinetics after single and repeated oral doses , 1981, Clinical pharmacology and therapeutics.

[237]  D. Alberts,et al.  Bleomycin pharmacokinetics in man. II. Intracavitary administration. , 1979, Cancer chemotherapy and pharmacology.

[238]  J. Volavka,et al.  Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment , 1975, Clinical pharmacology and therapeutics.

[239]  N. Benowitz,et al.  Pharmacokinetics of Haemoperfusion for Drug Overdose , 1979, Clinical pharmacokinetics.

[240]  P. Welling,et al.  Clinical Pharmacokinetics of Co-trimoxazole (trimethoprim-sulphamethoxazole) , 1980, Clinical pharmacokinetics.

[241]  R. Cutler,et al.  Clinical Pharmacokinetics of Frusemide , 1979, Clinical pharmacokinetics.

[242]  J. Aronson.  Clinical Pharmacokinetics of Digoxin 1980 , 1980, Clinical pharmacokinetics.

[243]  C. Comty,et al.  Digoxin pharmacokinetics in continuous peritoneal dialysis. , 1980, Annals of internal medicine.

[244]  M. Lewin,et al.  Therapeutic effect of cimetidine in patients undergoing haemodialysis. , 1979, British medical journal.

[245]  R. Brown,et al.  Acetazolamide and symptomatic metabolic acidosis in mild renal failure. , 1981, British medical journal.

[246]  D J Greenblatt,et al.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. , 1981, Annals of internal medicine.

[247]  R. Benjamin,et al.  Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. , 1977, Cancer research.

[248]  W. Bennett,et al.  Morphine and phenytoin binding to plasma proteins in renal and hepatic failure , 1975, Clinical pharmacology and therapeutics.

[249]  D. Grauman,et al.  Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. , 1979, Annals of internal medicine.

[250]  L. Sheiner,et al.  Renal function and the pharmacokinetics of neostigmine in anesthetized man. , 1979 .

[251]  J. Daugirdas,et al.  Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. , 1982, Clinical nephrology.

[252]  L. Ibels,et al.  Sulphinpyrazone-induced acute renal failure. , 1981, British medical journal.

[253]  D. Warren,et al.  Atenolol kinetics in renal failure , 1980, Clinical pharmacology and therapeutics.

[254]  N. Vaziri,et al.  Hemodialysis clearance of cimetidine. , 1978, Archives of internal medicine.

[255]  P. Massias,et al.  Sulfinpyrazone kinetics after intravenous and oral administration , 1979, Clinical pharmacology and therapeutics.

[256]  K. Iseki,et al.  Captopril (SQ 14225) clearance during hemodialysis treatment. , 1981, Clinical nephrology.

[257]  O. Wassermann,et al.  The Pharmacokinetics of Metoprolol and its Metabolites in Dialysis Patients , 1980, Clinical pharmacokinetics.

[258]  D. Sherrard,et al.  Chronic clofibrate therapy in maintenance hemodialysis patients. , 1980, Nephron.

[259]  J. Bigger,et al.  NEW DRUGS. , 1979, Canadian Medical Association journal.

[260]  A. Rosling,et al.  Renal function after acyclovir intravenous injection. , 1982, The American journal of medicine.

[261]  T. Depner,et al.  Impaired binding of drugs and endogenous ligands in renal diseases. , 1983, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[262]  C. Alling,et al.  Impairment of renal function in patients on long-term lithium treatment. , 1982, Clinical nephrology.

[263]  E. Nelson.  RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTION , 1964, The American journal of the medical sciences.

[264]  J. B. Hill,et al.  Renal and electrolyte disturbances associated with cisplatin. , 1981, Annals of internal medicine.

[265]  J J Schentag,et al.  Intravenous theophylline therapy: nomogram guidelines. , 1977, Annals of internal medicine.

[266]  M. Weber.  Discontinuation Syndrome Following Cessation of Treatment with Clonidine and Other Antihypertensive Agents , 1980, Journal of cardiovascular pharmacology.

[267]  R. Verbeeck,et al.  Biotransformation and excretion of lorazepam in patients with chronic renal failure. , 1976, British journal of clinical pharmacology.

[268]  A. Richens.  Clinical Pharmacokinetics of Phenytoin , 1979, Clinical pharmacokinetics.

[269]  R. Kimberly,et al.  Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. , 1978, The American journal of medicine.

[270]  L. Bertilsson.  Clinical Pharmacokinetics of Carbamazepine , 1978, Clinical pharmacokinetics.

[271]  N. Bank,et al.  The behavior of carbenicillin as a nonreabsorbable anion. , 1975, The Journal of laboratory and clinical medicine.

[272]  G. Levy,et al.  Hemodialysis clearance of theophylline. , 1977, JAMA.

[273]  E. Waller.  Pharmacokinetic Principles of Lidocaine Dosing in Relation to Disease State , 1981, Journal of clinical pharmacology.

[274]  L. Taclob,et al.  DRUG-INDUCED ENCEPHALOPATHY IN PATIENTS ON MAINTENANCE HEMODIALYSIS , 1976, The Lancet.

[275]  S. Rosenberg,et al.  Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. , 1977, The New England journal of medicine.

[276]  M. Greenstone,et al.  Acute nephrotic syndrome with reversible renal failure after phenylbutazone. , 1981, British medical journal.

[277]  H. Vöhringer,et al.  Digitalis therapy in renal failure with special regard to digitoxin. , 1981, International journal of clinical pharmacology, therapy, and toxicology.

[278]  J. Fillastre,et al.  Pharmacokinetics of cefadroxil in patients with impaired renal function. , 1982, The Journal of antimicrobial chemotherapy.

[279]  G. Levy.  Pharmacokinetics of salicylate in man. , 1979, Drug metabolism reviews.

[280]  T. Golper,et al.  Stability of antimicrobial agents in peritoneal dialysate , 1982, Antimicrobial Agents and Chemotherapy.

[281]  J. Aarbakke,et al.  Clinical Pharmacokinetics of Phenylbutazone , 1978, Clinical pharmacokinetics.

[282]  W. Haase,et al.  Single-dose pharmacokinetics of macrocrystalline nitrofurantoin formulations. , 1980, Arzneimittel-Forschung.

[283]  H. Neu,et al.  Pharmacokinetics of ticarcillin in patients with abnormal renal function. , 1976, The Journal of infectious diseases.

[284]  J. W. Findlay,et al.  Plasma codeine and morphine concentrations after therapeutic oral doses of codeine‐containing analgesics , 1978, Clinical pharmacology and therapeutics.

[285]  D. Rollins,et al.  Digitoxin elimination reduced during quinidine therapy. , 1981, Annals of internal medicine.

[286]  G. Levy.  Comparative pharmacokinetics of aspirin and acetaminophen. , 1981, Archives of internal medicine.

[287]  K. Desante,et al.  Benoxaprofen kinetics in renal impairment , 1982, Clinical pharmacology and therapeutics.

[288]  P. Routledge,et al.  Diazepam and lidocaine plasma protein binding in renal disease , 1982, Clinical pharmacology and therapeutics.

[289]  J. Strong,et al.  Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay , 1977, Cancer.

[290]  V. Torres.  Present and future of the nonsteroidal anti-inflammatory drugs in nephrology. , 1982, Mayo Clinic proceedings.

[291]  S. Garattini,et al.  Clinical Pharmacokinetics of Diazepam , 1978, Clinical pharmacokinetics.

[292]  D. Lowenthal,et al.  Pentobarbital elimination in patients with poor renal function , 1976, Clinical pharmacology and therapeutics.

[293]  R. Vestal,et al.  Propranolol disposition in renal failure. , 1980, British journal of clinical pharmacology.

[294]  D. Brahams.  Damages awarded for failed vasectomy. , 1984, Lancet.

[295]  L. Dettli,et al.  Influence of age and renal disease on aminoglycoside dosage. , 1981, The Journal of antimicrobial chemotherapy.

[296]  D. Edwards,et al.  Clinical Pharmacokinetics of Pethidine: 1982 , 1982, Clinical pharmacokinetics.

[297]  J. Daugirdas,et al.  Amantadine hydrochloride pharmacokinetics in hemodialysis patients. , 1980, Annals of internal medicine.

[298]  D. Bailey.  Colorimetry of serum acetaminophen (paracetamol) in uremia. , 1982, Clinical chemistry.

[299]  R. Graw,et al.  Chlorpropamide intoxication--treatment with peritoneal dialysis. , 1970, Pediatrics.

[300]  R. Owellen,et al.  Pharmacokinetics and metabolism of vinblastine in humans. , 1977, Cancer research.

[301]  A. Lorber.  Monitoring Gold Plasma Levels in Rheumatoid Arthritis , 1977, Clinical pharmacokinetics.

[302]  R. Weiss,et al.  Nephrotoxicity of streptozocin. , 1982, Annals of internal medicine.

[303]  L. Balant,et al.  Differences in Kinetic Properties of Drugs: Implications as to the Selection of a Particular Drug for Use in Patients with Renal Failure With Special Emphasis on Antibiotics and β-Adrenoceptor Blocking Agents , 1980, Clinical pharmacokinetics.

[304]  B. Svensson,et al.  Penicillamine treatment in rheumatoid arthritis. A retrospective study. , 2009, Acta medica Scandinavica.

[305]  R. Weiss,et al.  Enhanced bleomycin toxicity during acute renal failure. , 1982, Cancer treatment reports.

[306]  J. Fillastre,et al.  Pharmacokinetics of Azlocillin in Subjects with Normal and Impaired Renal Function , 1980, Antimicrobial Agents and Chemotherapy.

[307]  L. Balant.  Clinical Pharmacokinetics of Sulphonylurea Hypoglycaemic Drugs , 1981, Clinical pharmacokinetics.

[308]  Graham-Stewart Cw.  TERMINATION OF PREGNANCY ON PSYCHIATRIC GROUNDS. , 1964 .

[309]  R. Anderson,et al.  Prescribing Medication in Long-term Dialysis Units , 1982 .

[310]  T. Marbury,et al.  Hemodialysis of Theophylline in Uremic Patients , 1979, Journal of clinical pharmacology.

[311]  E. Casiglia,et al.  Effects of captopril on renal function in hypertensive patients. , 1982, The American journal of cardiology.

[312]  D. Greenblatt.  Clinical Pharmacokinetics of Oxazepam and Lorazepam , 1981, Clinical pharmacokinetics.

[313]  J. Bennett,et al.  Drugs Five Years Later: Bleomycin , 1979 .

[314]  Z. Israili.  Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man. , 1979, Annual review of pharmacology and toxicology.

[315]  C. Regårdh,et al.  Pharmacokinetic and Pharmacodynamic Properties of Metoprolol in Patients with Impaired Renal Function , 1980, Clinical pharmacokinetics.

[316]  E. Rapaport,et al.  Renal Effects of Nitroprusside and Hydralazine in Patients with Congestive Heart Failure , 1980, Circulation.

[317]  R. N. Brogden,et al.  Flunarizine , 2012, Drugs.

[318]  R. DeFronzo,et al.  CARBOHYDRATE METABOLISM IN UREMIA: A REVIEW , 1973, Medicine.

[319]  M. Newmark,et al.  Drug Spotlight Program: The Use of Antiepileptic Drugs , 1979 .

[320]  B. Beermann,et al.  Elimination of furosemide in healthy subjects and in those with renal failure , 1977, Clinical pharmacology and therapeutics.

[321]  M. Pinget,et al.  Pharamacokinetics of Cefazolin in Patients With Renal Failure; Special Reference to Hemodialysis , 1977, Journal of clinical pharmacology.

[322]  T. Walle,et al.  Massive propranolol metabolite retention during maintenance hemodialysis , 1980, Clinical pharmacology and therapeutics.

[323]  C. Regårdh,et al.  Clinical Pharmacokinetics of β-Adrenoceptor Blocking Drugs , 1976 .

[324]  R. Stitzel.  The biological fate of reserpine. , 1976, Pharmacological reviews.

[325]  J. Matsen,et al.  Gentamicin inactivation by piperacillin or carbenicillin in patients with end-stage renal disease , 1982, Antimicrobial Agents and Chemotherapy.

[326]  D. Latos,et al.  Carbenicillin therapy in patients with normal and impaired renal function , 1975, Clinical pharmacology and therapeutics.

[327]  F. Morady,et al.  Drugs Five Years Later: Disopyramide , 1982 .

[328]  R. Ronfeld.  Comparative pharmacokinetics of new antiarrhythmic drugs. , 1980, American heart journal.

[329]  T. Depner.  Nephrotic syndrome secondary to lithium therapy. , 1982, Nephron.

[330]  C. J. Mcallister,et al.  Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure. , 1978, Clinical Nephrology.

[331]  I. Sjöholm,et al.  Protein binding of diazepam and digitoxin in uremic and normal serum. , 1979, Biochemical pharmacology.

[332]  J. Burke,et al.  Doxorubicin hydrochloride-associated renal failure. , 1977, Archives of internal medicine.

[333]  E. Atkin-thor,et al.  Gentamicin and ticarcillin in subjects with end-stage renal disease. Comparison of two assay methods and evaluation of inactivation rate. , 1981, Clinical nephrology.

[334]  R. Branch,et al.  Meperidine disposition in man: Influence of urinary pH and route of administration , 1981, Clinical pharmacology and therapeutics.

[335]  F. Luft,et al.  Effect of Cephalothin on Measurement of Creatinine Concentration , 1979, Antimicrobial Agents and Chemotherapy.

[336]  R. Pearson.  Pharmacokinetics and Response to Diazoxide in Renal Failure , 1977, Clinical pharmacokinetics.

[337]  K. Lange.  Nephropathy induced by D-penicillamine. , 1978, Contributions to nephrology.

[338]  J. Briggs,et al.  The administration of cephradine to patients in renal failure. , 1975, British journal of clinical pharmacology.

[339]  W. Pettinger,et al.  Renal function during long-term treatment of hypertension with minoxidil: comparison of benign and malignant hypertension. , 1980, Annals of internal medicine.

[340]  K. Alestig,et al.  Renal function during cefoperazone treatment. , 1982, Journal of Antimicrobial Chemotherapy.

[341]  J. Bitran,et al.  Acute nephrotoxicity following cis‐dichlorodiammine‐platinum , 1982, Cancer.

[342]  W. Bleyer,et al.  Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. , 1978, Archives of internal medicine.

[343]  J. Pederson,et al.  Pharmacokinetics of Cefamandole in Patients with Renal Impairment , 1979, Antimicrobial Agents and Chemotherapy.

[344]  R. Golbey,et al.  High dose Cis‐platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis , 1977, Cancer.

[345]  S. Ehrlich,et al.  Ceftizoxime kinetics and renal handling , 1982, Clinical pharmacology and therapeutics.

[346]  E. Kirsten,et al.  The Pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses , 1982 .

[347]  S. Textor,et al.  Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. , 1982, The American journal of medicine.

[348]  K. Kessler,et al.  Decreased quinidine plasma protein binding during hemodialysis , 1981, Clinical pharmacology and therapeutics.

[349]  R. Fisher,et al.  Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. , 1981, The American journal of medicine.

[350]  W. Procci.  Mania during maintenance hemodialysis successfully treated with oral lithium carbonate. , 1977, The Journal of nervous and mental disease.

[351]  W. Craig,et al.  Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function. , 1983, Reviews of infectious diseases.

[352]  R. Stolfi,et al.  Rationale of combined modality therapy for cancer. , 1974, Cancer chemotherapy reports. Part 2.

[353]  E. Myhre,et al.  Clinical Pharmacokinetics of Methyldopa , 1982, Clinical pharmacokinetics.

[354]  S. Silvis,et al.  Effects of renal failure on blood levels of cimetidine. , 1978, Gastroenterology.

[355]  D. Blair,et al.  Inactivation of amikacin and gentamicin by carbenicillin in patients with end-stage renal failure , 1982, Antimicrobial Agents and Chemotherapy.

[356]  G. Boner,et al.  Effects of pindolol on renal function , 1980, Clinical pharmacology and therapeutics.

[357]  I. Odar-Cederlof.  Plasma Protein Binding of Phenytoin and Warfarin in Patients Undergoing Renal Transplantation , 1977, Clinical pharmacokinetics.

[358]  W. R. Fox,et al.  Electrolyte Excretion Patterns. Intravenous and Oral Doses of Bumetanide Compared to Furosemide , 1981, Journal of clinical pharmacology.

[359]  J. Velosa,et al.  Acute intrinsic renal failure induced by indomethacin: role of prostaglandin synthetase inhibition. , 1982, Mayo Clinic proceedings.

[360]  C. Enderle,et al.  Elimination and serum protein binding of phenylbutazone in patients with renal insufficiency. , 1976, Clinical nephrology.

[361]  A. Meek,et al.  Guidelines for the Use of Thrombolytic Agents , 1979 .

[362]  R. Cutler,et al.  Cefadroxil kinetics in patients with renal insufficiency , 1979, Clinical pharmacology and therapeutics.

[363]  W. Frishman,et al.  β-Adrenoceptor Antagonists: New Drugs and New Indications , 1981 .

[364]  R. Bressler,et al.  Clinical Pharmacology of Oral Antidiabetic Agents , 1977 .

[365]  K. Isselbacher,et al.  Drug therapy: Cimetidine. , 1978, The New England journal of medicine.

[366]  L. Regeur,et al.  Pharmacokinetics of Amikacin During Hemodialysis and Peritoneal Dialysis , 1977, Antimicrobial Agents and Chemotherapy.

[367]  L. Einhorn,et al.  The role of cis-platinum in solid-tumor therapy. , 1979, The New England journal of medicine.

[368]  H. E. Hansen,et al.  Chronic renal lesions following long-term treatment with lithium. , 1977, Kidney international.

[369]  J. Kroener,et al.  Cyclophosphamide dose in renal failure. , 1978, The American journal of medicine.

[370]  R. Rabkin,et al.  Effect of renal disease on renal uptake and excretion of insulin in man. , 1970, The New England journal of medicine.

[371]  J. Kelly,et al.  Clinical Pharmacokinetics of Oral Anticoagulants , 1979, Clinical pharmacokinetics.

[372]  T. Ludden,et al.  Variability of plasma hydralazine concentrations in male hypertensive patients. , 1981, Arthritis and rheumatism.

[373]  J. Pritchard,et al.  Effect of dose and uremia on plasma and urine profiles of propranolol metabolites , 1980, Clinical pharmacology and therapeutics.

[374]  R. Mason,et al.  Protein binding of indomethacin: binding of indomethacin to human plasma albumin and its displacement from binding by ibuprofen, phenylbutazone and salicylate, in vitro. , 1974, Pharmacology.

[375]  R. Gugler.  Clinical Pharmacokinetics of Hypolipidaemic Drugs , 1978, Clinical pharmacokinetics.

[376]  D. Drayer,et al.  Drug therapy in renal failure. , 1980, Annual review of pharmacology and toxicology.

[377]  D. Brater,et al.  Nomograms for Drug Use in Renal Disease , 1981, Clinical pharmacokinetics.

[378]  H. Langrall,et al.  Adverse reactions to pindolol administration. , 1982, American heart journal.

[379]  F. Finkelstein,et al.  Effect of Peritoneal Dialysis on Serum Levels of Tobramycin and Clindamycin , 1975, Antimicrobial Agents and Chemotherapy.

[380]  J. D. Conklin.  The pharmacokinetics of nitrofurantoin and its related bioavailability. , 1978, Antibiotics and chemotherapy.

[381]  Vandam Ld.  Drug therapy: butorphanol. , 1980, The New England journal of medicine.

[382]  H. Szeto,et al.  Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. , 1977, Annals of internal medicine.

[383]  I. Hansen.  Clinical Pharmacokinetics of Co-trimoxazole , 1983 .

[384]  R. Slaughter,et al.  Lidocaine Clinical Pharmacokinetics , 1982, Drug intelligence & clinical pharmacy.

[385]  W. Pettinger,et al.  Drug therapy. Prazosin. , 1979, The New England journal of medicine.

[386]  J. Fillastre,et al.  Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients. , 1978, The Journal of antimicrobial chemotherapy.

[387]  A. Nissenson,et al.  Moxalactam kinetics in hemodiaiysis , 1981 .

[388]  A. Teien,et al.  Heparin elimination in uraemic patients on Haemodialysis. , 2009, Scandinavian journal of haematology.

[389]  M. Pfeffer,et al.  Ceforanide kinetics in renal insufficiency , 1981, Clinical pharmacology and therapeutics.

[390]  K. Giacomini,et al.  Effect of hemodialysis on propoxyphene and norpropoxyphene concentrations in blood of anephric patients * , 1980, Clinical pharmacology and therapeutics.

[391]  A. Sebastian,et al.  Pathophysiology of chronic renal tubular acidosis induced by administration of amiloride. , 1980, The Journal of laboratory and clinical medicine.

[392]  J. Weening,et al.  IMMUNE-COMPLEX GLOMERULOPATHY IN PATIENTS TREATED WITH CAPTOPRIL , 1980, The Lancet.

[393]  G. Acocella.  Clinical Pharmacokinetics of Rifampicin , 1978, Clinical pharmacokinetics.

[394]  B. Petitpierre,et al.  Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy. , 1972, International journal of clinical pharmacology, therapy and toxicology.

[395]  D. Brater,et al.  Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. , 1981, Annals of internal medicine.

[396]  B. Flouvat,et al.  Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. , 1980, British journal of clinical pharmacology.

[397]  T. Gallagher,et al.  Metabolism of 35S-labelled Antithyroid Drugs in Man , 1969, British medical journal.

[398]  T. Marbury,et al.  Clearance and recovery calculations in hemodialysis: Application to plasma, red blood cell, and dialysate measurements for cyclophosphamide , 1981, Clinical pharmacology and therapeutics.

[399]  C H Nightingale,et al.  Pharmacokinetics of vancomycin in anuria. , 1981, Reviews of infectious diseases.

[400]  V. Manninen,et al.  Hypolipidæmic Action of Gemfibrozil in Adult Nephrotics , 1976, Proceedings of the Royal Society of Medicine.

[401]  G. Mcinnes,et al.  Dose‐response relationships for spironolactone at steady state , 1982, Clinical pharmacology and therapeutics.

[402]  W. Wolberg,et al.  Pharmacokinetics of fluorouracil in humans. , 1978, Cancer research.

[403]  M. Ogilvie,et al.  Carbenicillin-induced coagulopathy. , 1970, Lancet.

[404]  A. Gelenberg,et al.  Hazards and adverse effects of lithium. , 1982, Annual review of medicine.

[405]  W. Weber,et al.  Clinical Pharmacokinetics of Isoniazid , 1979, Clinical pharmacokinetics.

[406]  Jerome J. Schentag,et al.  Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients , 1981, Antimicrobial Agents and Chemotherapy.

[407]  J. Sheehan,et al.  Hazards of phenothiazines in chronic renal failure. , 1982, Irish medical journal.

[408]  G. Appel,et al.  Kinetics of intravenous amoxicillin in patients on long‐term dialysis , 1979, Clinical pharmacology and therapy.

[409]  C. Ruckley,et al.  A 5 year follow up of lords dilation for hemorrhoids , 1976 .

[410]  E. Michelson,et al.  Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. , 1980, Kidney international.

[411]  N. Benowitz,et al.  Pharmacokinetics of Drug Overdose , 1981, Clinical pharmacokinetics.

[412]  M. Vallotton,et al.  Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. , 1982, Annals of internal medicine.

[413]  J. Gal,et al.  Serum Binding of Diltiazem in Humans , 1982, Journal of clinical pharmacology.

[414]  W. Bennett,et al.  Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. , 1980, Cancer treatment reports.

[415]  R. Ohman,et al.  Studies on serum protein binding of haloperidol. , 1977, Current therapeutic research, clinical and experimental.